20-F: Molecular Partners 2025: Pipeline Advances, Losses Persist

Molecular Partners AG reported continued net losses in 2025, alongside significant progress in its oncology pipeline, including the initiation of new clinical trials and expansion of strategic collaborations for its DARPin therapeutics.

Summary

• Reported a net loss attributable to shareholders of CHF 61.7 million for the year ended December 31, 2025, compared to CHF 54.0 million in 2024 and CHF 62.0 million in 2023.
• Cumulative losses reached CHF 311.8 million as of December 31, 2025.
• Revenue from research and development collaborations was zero in 2025, a decrease from CHF 4.97 million in 2024, as the Novartis radioligand agreement concluded in Q3 2024.
• Total operating expenses decreased by CHF 7.9 million to CHF 58.1 million in 2025 (2024: CHF 66.1 million, 2023: CHF 68.1 million).
• Research and development expenses were CHF 40.2 million in 2025, down from CHF 48.6 million in 2024 and CHF 48.8 million in 2023, primarily due to cost reductions for MP0533 and MP0317.
• Selling, general and administrative expenses decreased by CHF 2.4 million (14%) to CHF 15.2 million in 2025, mainly due to reductions in Directors and Officers insurance and professional service costs.
• Recorded CHF 2.7 million in restructuring expenses in 2025, impacting 34 employees, primarily in R&D.
• Cash and cash equivalents plus short-term time deposits stood at CHF 93.1 million as of December 31, 2025, expected to fund operations until 2028.
• Initiated a Phase 1/2a trial for MP0712 (DLL3-targeting Radio-DARPin) in the United States in December 2025, with initial clinical data expected in 2026.
• An investigator-initiated Phase 2 trial for MP0317 (FAP-localized CD40 agonist) in advanced cholangiocarcinoma began in January 2026, with initial data expected in 2027.
• MP0533 (tetra-specific T-cell engager) Phase 1/2a trial is ongoing, with densified dosing showing improved serum exposure and antitumor activity in cohort 8, and cohort 10 currently dosing patients.
• Expanded strategic collaboration with Orano Med to co-develop up to ten 212Pb-based Radio-DARPin Therapy programs.
• Entered a development agreement with Eckert & Ziegler for targeted alpha radio-therapeutics, including 225Ac.
• Formed a scientific advisory board in December 2025 to accelerate targeted radiotherapeutics development.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative report due to persistent and increasing net losses, the complete cessation of collaboration revenue in 2025, and significant restructuring costs. While pipeline progress and new collaborations offer future potential, the immediate financial performance is concerning and highlights ongoing funding needs.

Positives

• Initiation of Phase 1/2a trial for lead Radio-DARPin candidate MP0712 in December 2025, targeting DLL3 for SCLC and other neuroendocrine cancers.
• Positive early patient imaging and dosimetry data for MP0712 (203Pb-labeled) from a compassionate care program, showing specific tumor uptake and limited healthy tissue uptake.
• Strong preclinical data package for MP0712 demonstrating high affinity, specificity, promising biodistribution, safety, and antitumor activity.
• Initiation of an investigator-initiated Phase 2 proof-of-concept trial for MP0317 in advanced cholangiocarcinoma in January 2026, combining with standard-of-care.
• MP0533 Phase 1/2a trial showed improved serum exposure and antitumor activity with densified dosing in cohort 8, particularly in patients with low bone marrow blast count.
• Expanded strategic collaboration with Orano Med to co-develop up to ten 212Pb-based Radio-DARPin Therapy programs.
• Development agreement with Eckert & Ziegler enables exploration of Radio-DARPins with a range of therapeutic isotopes, including 225Ac.
• Formation of a Scientific Advisory Board in December 2025 to guide targeted radiotherapeutics development.
• DARPin platform's intrinsic advantages: high affinity and specificity, small size, multispecificity, either-or specificity (Switch-DARPins), high stability, precision delivery, tunable half-life, and high-yield microbial manufacturing.
• Cash and cash equivalents plus short-term time deposits of CHF 93.1 million are expected to fund operating expenses and capital expenditure requirements into 2028.

Negatives

• Continued significant net losses, with CHF 61.7 million in 2025, CHF 54.0 million in 2024, and CHF 62.0 million in 2023.
• Cumulative losses reached CHF 311.8 million as of December 31, 2025.
• Revenue from research and development collaborations dropped to zero in 2025 due to the conclusion of the Novartis radioligand agreement.
• Termination of the Ensovibep License Agreement in January 2024 and return of rights by Novartis, with the program remaining terminated.
• Restructuring expenses of CHF 2.7 million incurred in 2025 due to an operational efficiency initiative, affecting 34 employees.
• MP0533 initial activity showed unsustained responses in early dose escalation cohorts, requiring protocol amendments for dose densification.
• The base patents for the DARPin technology licensed from the University of Zurich expired in September 2021 (except one US patent, which expired in August 2023), potentially allowing competitors to use the technology.
• The company has never generated revenue from product sales and may never achieve profitability.
• The company may need substantial additional funding in the future, and failure to obtain it could delay, limit, or terminate product development.
• The company's status as a Swiss corporation limits flexibility in raising capital compared to U.S. companies.
• Potential for product candidates to have serious adverse side effects, which could delay or prevent marketing approval or limit commercial profile.
• Intense competition in the pharmaceutical and biotechnology industries, with many competitors having greater resources.
• Reliance on third parties for manufacturing and clinical trials exposes the company to risks of delays, quality issues, and supply disruptions.
• Exposure to costly and damaging liability claims, with insurance potentially not covering all damages.
• Subject to stringent and changing U.S. and foreign laws, regulations, and contractual obligations related to privacy, data protection, and security, with potential for significant penalties for non-compliance.
• Exposure to anti-corruption laws, export control laws, customs laws, and sanctions laws, with potential for civil or criminal penalties for non-compliance.
• Risk of being classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, which could lead to adverse tax consequences for U.S. Holders.

Risks

• Significant operating losses and expectation to incur losses in future periods, potentially not achieving profitability.
• Need for substantial additional funding to complete development and commercialization of product candidates; failure to obtain capital may force delays or termination of operations.
• Raising additional capital may dilute existing shareholders and incur restrictive covenants if debt financing is used.
• Heavy dependence on the success of the DARPin platform; failure to develop and commercialize product candidates based on it would harm the business.
• All product candidates are in preclinical or various stages of clinical development; clinical drug development is lengthy, expensive, and has uncertain outcomes, potentially leading to delays or inability to commercialize.
• Preclinical drug development is uncertain; programs may experience delays or never advance to clinical trials.
• Positive results from early preclinical studies are not necessarily predictive of later results.
• Interim, topline, and preliminary clinical trial data may change as more patient data become available and are subject to audit and verification.
• Small patient numbers in certain clinical trials may lead to less reliable results.
• Product candidates may have serious adverse side effects, potentially delaying or preventing marketing approval, limiting commercial profiles, or leading to product liability claims.
• Negative side effects from one product candidate could adversely affect public perception of the entire DARPin platform and other candidates.
• Significant competition in drug discovery and development, potentially reducing or eliminating commercial opportunities.
• Financial prospects are dependent on the research, manufacture, development, and marketing efforts of licensees, who may act in their own best interest.
• Reliance on patents and other intellectual property rights for protection is challenging and costly; failure to obtain, maintain, enforce, or protect these rights adequately could harm competitiveness.
• Risk of third parties initiating legal proceedings alleging infringement, misappropriation, or other violation of their intellectual property rights, leading to uncertain outcomes, substantial resource expenditure, and distraction of personnel.
• Base patents relating to the DARPin technology have expired, allowing competitors to use the technology.
• Certain significant shareholders may exercise significant influence over shareholder votes, potentially with different interests.
• Dependence on information technology systems and third parties; compromises could lead to adverse consequences including regulatory actions, litigation, and reputational harm.
• Exposure to costly and damaging liability claims, with product liability insurance potentially insufficient.
• Clinical trials conducted outside the U.S. may not have data accepted by the FDA or similar foreign regulatory authorities.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable; failure to obtain approval would substantially harm the business.
• Ongoing obligations and continued regulatory review post-approval may result in significant additional expense, labeling restrictions, or market withdrawal.
• Limited resources necessitate prioritization of certain product candidates, which may prove to be incorrect decisions.
• Enacted and future legislation (e.g., ACA, OBBBA, Pharma Package in EU) may increase difficulty and cost of obtaining marketing approval and affect pricing.
• Subject to healthcare laws, regulation, and enforcement (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, GDPR); non-compliance could lead to civil/criminal penalties.
• Successful commercialization depends on adequate reimbursement levels and pricing policies by governmental authorities and health insurers.
• Failure to successfully identify, develop, and commercialize additional products could impair growth.
• Service or supply failures, business interruptions, or disasters affecting manufacturing facilities of supply chain partners would adversely affect product supply.
• Developing product candidates in combination with other therapies exposes the company to additional risks related to those therapies.
• Current and potential future use of AI presents new risks and challenges, including cybersecurity, competitive harm, and regulatory scrutiny.
• Research and development activities could be affected or delayed by restrictions on animal testing.
• Exposure to environmental, health, and safety laws and regulations, potentially leading to liability and substantial expenses.
• Employees, contractors, and partners may engage in misconduct or improper activities.
• High dependency on public perception of products.
• Risks associated with international operations, including economic, political, and regulatory factors, and exchange rate fluctuations.
• Unanticipated changes in tax laws and regulations, adjustments to tax provisions, or forfeiture of tax assets.
• Volatility in the price of ADSs due to various factors beyond control.
• Increased costs and management time due to operating as a U.S.-listed public company.
• Provisions of articles of association or Swiss corporate law might deter acquisition bids.
• Fluctuations in exchange rates may increase the risk of holding ADSs and ordinary shares.
• Trading on multiple markets may result in price variations and affect liquidity.
• ADS holders are not treated as holders of ordinary shares and may have limited voting rights or transfer limitations.
• Company can amend or terminate deposit agreement without prior consent of ADS holders.
• ADS holders may not be entitled to a jury trial.
• Beneficial owners not registered in the shareholders register may not exercise certain rights.
• No expectation of dividends in the foreseeable future.
• Non-Swiss shareholders and ADS holders may not be able to exercise pre-emptive rights.
• Swiss corporate law may provide different protections than U.S. jurisdictions.
• Claims of U.S. civil liabilities may not be enforceable against the company in Switzerland.
• Loss of foreign private issuer status would require compliance with U.S. domestic reporting regime, increasing costs.
• As an "emerging growth company," reduced reporting requirements may make ADSs less attractive.
• Failure to maintain effective internal control over financial reporting could harm business and share price.
• Securities litigation is expensive and could divert management attention.

Future Outlook

The company expects its existing cash, cash equivalents, and anticipated funding through collaborations to fund operating expenses and capital expenditure requirements into 2028. It plans to continue expanding its development, regulatory, and sales and marketing capabilities, which will increase operating expenses. The company aims to progress its lead Radio-DARPin candidate MP0712, additional Radio-DARPin candidates like MP0726, and nominate new targets for its growing Radio-DARPin pipeline. It will also support the ongoing Phase 2 trial of MP0317 and conclude the dose escalation for MP0533, with plans to explore combination therapies. The company intends to nominate a lead Switch-DARPin candidate in the first half of 2026 and continue strategic in-house versus partnered development.

Management Comments

• We believe our DARPin drug candidates can close the gap between small molecule and antibody medicines as a new therapeutic modality poised to offer clinical breakthroughs.
• We are committed to leveraging our proprietary DARPin platforms and drug design engine to design DARPin-unique solutions for challenges other therapies cannot readily address.
• We expect initial clinical data from the MP0712 trial in 2026.
• We expect initial data from the MP0317 Phase 2 trial in 2027.
• We plan to support the exploration of MP0533 in combination therapy, both in patients with relapsed/refractory disease as well as in front-line, and has been approached by several consortia expressing interest in conducting such trials.
• We expect to provide an update on the MP0533 program and clinical plan during the first half of 2026.
• We intend to nominate a lead Switch-DARPin candidate for development in the first half of 2026 and intend to provide an update on the program at the AACR Annual Meeting in April 2026.
• We believe that our DARPin platform has the potential to yield novel product candidates with broad therapeutic application given their ability to overcome many of the limitations of antibody and other conventional protein-based therapeutics.
• We believe our current facilities are sufficient to meet our short-term needs.
• We believe that these financial institutions are of high credit quality and continually monitor the credit worthiness of these financial institutions.

Industry Context

StockSavvy.ai notes that Molecular Partners AG operates in the highly competitive biopharmaceutical industry, particularly in oncology, which is characterized by rapid technological change and significant unmet medical needs. The company's focus on DARPin therapeutics, a novel class of custom-built protein drug candidates, positions it to address challenges not readily met by traditional antibodies or small molecules. The expansion of its Radio-DARPin Therapy (RDT) platform and collaborations with entities like Orano Med and Eckert & Ziegler align with the growing trend in targeted radiotherapies. The company's pipeline, including immune cell engagers, reflects the industry's shift towards more precise and conditionally activated immune responses to mitigate toxicity, a common challenge in immuno-oncology. The termination of the Ensovibep agreement with Novartis highlights the inherent risks and rapid shifts in therapeutic priorities within the biopharmaceutical sector, especially in areas like COVID-19 treatments.

Comparison to Industry Standards

• The DARPin platform's ability to design multi-specific molecules with high affinity, specificity, small size, and high stability offers potential advantages over conventional antibody-based therapeutics, which often face limitations in tissue penetration and manufacturing complexity.
• The company's RDT platform addresses key challenges of radioligand therapeutics, such as kidney retention and suboptimal tumor uptake, through surface engineering and half-life extension technologies, aiming for improved tumor uptake and reduced kidney reabsorption compared to other radioligand therapies.
• MP0317's design for localized CD40 activation in FAP-high tumor tissue aims to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies, which have been associated with mild to moderate toxicity (e.g., CRS and liver toxicity).
• MP0533's tetra-specific T-cell engaging design, targeting CD33, CD123, and CD70 on AML cells and CD3 on T cells, is intended to enable T cell-mediated killing of AML cells while minimizing damage to healthy cells, differentiating it from other biologics and small molecules in the competitive hematologic cancer market.
• The Switch-DARPin TCEs, designed for conditional tumor-localized immune activation and co-stimulation, aim to overcome challenges of high toxicity and limited specificity often faced by other immuno-oncology therapies, particularly against solid tumors.
• The company's high-yield microbial manufacturing process for DARPin candidates offers competitive advantages over mammalian cell line production, including faster clinical batch manufacturing (7-10 days vs. 30 days) and high production yield (12-15g/L).

Management Changes

Corporate Governance

Legal Proceedings

• A securities class action complaint was filed in the U.S. District Court for the Southern District of New York in July 2022, alleging misrepresentations and omissions regarding product candidate MP0310 and an associated licensing agreement.
• An amended complaint was filed on May 23, 2023, seeking unspecified compensatory damages and attorneys' fees.
• The court dismissed the amended complaint without prejudice on February 5, 2024, allowing the plaintiff to amend by February 26, 2024.
• The plaintiff filed a stipulation of dismissal with prejudice on February 23, 2024.
• The court ordered the case closed on February 29, 2024.

Related Party Transactions

• The company has entered into customary employment agreements with all executive officers, providing for base salary, annual incentive bonus, and participation in equity incentive plans, with a general six-month advance notice of termination.
• Indemnification agreements have been entered into with each director and executive officer.
• The company has a related person transaction policy for identifying, reviewing, considering, and approving or ratifying transactions exceeding $120,000 or unusual in nature, with approval by the Audit and Finance Committee or another independent board body.
• Swiss law and the company's articles of association impose specific rules for transactions with board members and executive management, including limitations on fixed-term employment contracts, non-competition agreements (max two years, compensation not exceeding last annual total compensation), and loans (max double last annual total compensation at market rates).
• Post-retirement benefits beyond the occupational benefit scheme for board members and executive management require shareholder approval and may not exceed 100% of the last paid annual compensation.

Stakeholder Impact

• Shareholders: Continued losses and need for future funding pose dilution risk. Pipeline progress and new collaborations offer potential for long-term value. Share price volatility is a risk. Limited voting rights for ADS holders. No dividends expected.
• Employees: Restructuring in 2025 affected 34 employees. Equity incentive plans (PSUs, RSUs) are in place to align interests and retain talent.
• Customers/Patients: Development of novel DARPin therapeutics, particularly in oncology and radiopharmaceuticals, aims to provide new treatment options with higher efficacy and fewer adverse events for high unmet medical needs.
• Collaborators: Ongoing and expanded partnerships (Orano Med, Eckert & Ziegler) are crucial for funding and development, but reliance on partners carries risks of misalignment or termination (e.g., Novartis Ensovibep).
• Creditors: The company's secure cash position (CHF 93.1 million) and low liquidity risk are positive for creditors, but persistent losses and future funding needs remain a consideration.
• Regulatory Bodies: Ongoing compliance with extensive U.S. and international regulations (FDA, EMA, Swiss laws) is critical for product development and commercialization.

Next Steps

• Initiate a new clinical trial of MP0317 (in combination with other therapies).
• Continue to prepare for and complete and potentially expand the Phase 1 clinical trial of MP0533.
• Continue to prepare for and initiate the Phase 1 clinical trial of MP0712.
• Continue to prepare for and potentially initiate a Phase 0 and Phase 1 clinical trial of MP0726.
• Seek to enhance the DARPin technology and build on the proprietary product pipeline.
• Continue research activities for MP0712 and other suitable candidates within the Radio DARPin Therapy space.
• Continue research and development of other clinicaland preclinical-stage product candidates and discovery stage programs.
• Seek regulatory approvals for any product candidates that successfully complete clinical trials.
• Establish a sales, marketing, and distribution infrastructure and scale-up manufacturing capabilities to commercialize approved product candidates.
• Obtain, maintain, expand, protect, and enforce intellectual property and other proprietary rights.
• Add clinical, regulatory, scientific, operational, financial, legal, intellectual property, compliance, and management information systems and personnel.
• Provide an update on the MP0533 program and clinical plan during the first half of 2026.
• Nominate a lead Switch-DARPin candidate for development in the first half of 2026.
• Provide an update on the Switch-DARPin program at the AACR Annual Meeting in April 2026.
• Present pre-clinical data on Radio-DARPins suitability with multiple isotopes at the 3rd Global Radiopharmaceuticals Development Summit in March 2026.
• Evaluate MP0621 for partnering.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' for Molecular Partners AG. While the company faces significant financial headwinds, including persistent losses and a lack of product revenue, its robust and advancing DARPin pipeline, particularly in targeted radiotherapeutics and immune cell engagers, presents substantial long-term potential. The expanded collaborations and positive early clinical data for key candidates like MP0712 and MP0533 are encouraging. However, the early stage of most programs, the high capital requirements, and the inherent risks of drug development warrant caution. Investors should monitor clinical trial progress and future financing activities closely.

Keywords

DARPin therapeutics, oncology, radiopharmaceuticals, immune cell engagers, clinical-stage biotechnology, MP0712, DLL3, SCLC, MP0317, FAP, CD40, cholangiocarcinoma, MP0533, AML, MDS, CD3, CD70, CD123, CD33, Switch-DARPins, MSLN, EpCAM, Orano Med, Eckert & Ziegler, 212Pb, 225Ac, biotechnology, drug development, clinical trials, SEC filing, 20-F, Molecular Partners AG